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One of the major surgical challenges in the field of 
regenerative medicine has been the reconstruction 
of large bony defects in the maxillofacial region. 
The autogenous bone grafts have always been the 
gold standard for maxillofacial reconstruction; they 
facilitate osteoconduction, osteoinduction, and 
osteogenesis. Osteoconduction occurs when the bone 
graft  material serves as a scaﬀ old for new bone growth 
that is perpetuated by the native bone. Osteoinduction 
involves the stimulation of osteoprogenitor cells to 
diﬀ erentiate into osteoblasts for the formation of new 
bone. Osteogenesis occurs when vital osteoblasts 
originating from the bone graft  material contribute 
to new bone growth. However, the harvesting of 
autogenous bone graft is associated with donor 
site morbidities and limited availability. These 
restrictions inspired the researchers across the world 
to engineer tissue to replace the lost one. Tissue 
engineering was initially introduced to describe the 
synthesis of biological tissue in vitro. Recently, the term 
“regenerative medicine” has been used to describe 
the development of technology for the regeneration 
of tissue in vivo. The objectives of tissue engineering 
and regenerative medicine are to promote healing, 
and ideally, true regeneration of a tissue structure and 
function more predictably and less invasively than the 
previous graft ing techniques.
Bone tissue bioengineering originated with the 
introduction of 3D biomaterial scaffolds to support 
the regeneration and to replace the need for autogenous 
bone graft. However, osteogenesis in these large 
scaffolds occurred primarily on the outer surfaces, 
indicating a nonhomogenous distribution of cells 
and a predominantly osteoconductive rather than 
osteoinductive pattern of bone formation. The 
introduction of bone mesenchymal stem cells (MSCs) 
has been tested in the repair of large bony defects in 
animal models and in humans, with variable degrees 
of success.In these studies, expanded MSCs seeded 
onto various scaﬀ olds were applied in animal models; 
the reported success was variable and dependent on 
the animal species, the animal’s age, the methodology 
of MSC culture and its expansion, the cell seeding 
technique, and the scaﬀ old type and its geometry. The 
major turning point in the arena of bone reconstruction 
is the introduction of bone morphogenic proteins 
(BMPs). BMPs are osteoinductive, and at the level 
of preclinical research, the use of BMP has shown 
promising results. The clinical applications are still 
limited.
One of the major obstacles of a successful bone 
bioengineering is the compromised vascularity 
at the graft site due to previous radiotherapy or a 
vascular disease. In an att empt to solve this problem, 
a prefabricated tissue engineered graft which was 
transferred in pedicled fl aps has been considered with a 
moderate degree of success. Further studies are required 
to improve the blood supply at the surgical site.
There is no doubt that enormous progress has been 
made over the last 40 years. The application of tissue 
engineering and prefabrication scaffolding showed 
great and exciting promising results at preclinical and in 
some clinical studies. Yet, refi nement of the technique, 
identifi cation of the ideal scaﬀ olding, and improving 
the vascularity at the surgical site are necessary.
It is our opportunity and responsibility to forge and 
establish links with the multidisciplinary team of 
investigators to take the research from the lab to the 
patients’ side, which is essential to fulfi l our clinical 
and academic aspirations.
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